

Click For [Full Prescribing Information](#) for SOLU-CORTEF® (hydrocortisone sodium succinate for injection, USP)

**Pfizer Inc.**

275 North Field Drive  
Lake Forest, IL 60045



April 14, 2025

**Availability Update for Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL® Single Dose Vial (25-pack) Presentation**

Dear Valued Customer,

Pfizer Hospital is committed to providing the most up-to-date supply information so that you can plan for patient care. As such, we want to notify you that we are having a short-term interruption in the supply of **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL® Single Dose Vial (25-pack), NDC 00009-0011-04**, due to increased demand and a manufacturing delay that has now been resolved. The U.S. Food and Drug Administration (FDA) has been notified.

We understand the importance of this product to customers and patients and are actively working to return to healthy inventory levels. Based on the 80% wholesaler allocation currently in place on **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL® Single Dose Vial (25-pack), NDC 00009-0011-04**, we anticipate wholesalers to have approximately 5 weeks of product remaining to meet demand. Next delivery is estimated for June 2025, and we anticipate a full recovery—when we have cleared all backorders in addition to maintaining several weeks of safety stock in our distribution centers—in 3Q 2025, as noted in the Product Table below.

Pfizer anticipates the potential for increased demand on all other Solu-Cortef® presentations as a result of this supply interruption and is taking proactive steps to manage inventory to ensure fair and equitable distribution. All other Solu-Cortef® presentations will be available via wholesaler only, with weekly releases of 100% to

125% of historical purchases, as noted in the Product Table below. These presentations are not impacted by the manufacturing delay.

Pfizer will also reserve limited quantities of **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL® Single Dose Vial (1 pack), NDC 00009-0011-03** and **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg Fliptop Vial (1 pack), NDC 00009-0825-01**, for emergency situations in which allocated inventory is not sufficient to support patient needs.

In these situations, Pfizer will distribute available inventory direct to customers in accordance with its emergency request process, which requires that customers complete the attached emergency request form. Completed forms should be emailed to [PISupplyContinuity@pfizer.com](mailto:PISupplyContinuity@pfizer.com). Requests will be reviewed and filled in the order they are received, and only with the completed documentation. Cut off time for overnight requests is 3 p.m. (CT). Overnight shipments will incur a \$25 Shipping & Handling fee and a variable shipping charge based on the weight of the product.

Unit of Sale NDC	Product Description	Unit of Sale Size	Ordering & Shipping Method	Next Delivery	Estimated Recovery	Weekly Release % of Historical Demand
00009-0011-04	Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL® Single Dose Vial	25	Wholesaler, Distributor Only	06/2025	3Q 2025	---
00009-0011-03	Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL® Single Dose Vial	1	Wholesaler, Distributor Only	04/2025	3Q 2025	125%
00009-0825-01	Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg Vial	1	Wholesaler, Distributor Only	04/2025	3Q 2025	125%
00009-0013-06	Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 250 mg/2 mL (125 mg/mL) ACT-O-VIAL® Single Dose Vial	25	Wholesaler, Distributor Only	04/2025	3Q 2025	100%
00009-0013-05	Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 250 mg/2 mL (125 mg/mL) ACT-O-VIAL® Single Dose Vial	1	Wholesaler, Distributor Only	04/2025	3Q 2025	100%

00009-0016-12	Solu-Cortef <sup>®</sup> (hydrocortisone sodium succinate for injection, USP) 500 mg/4 mL (125 mg/mL) ACT-O-VIAL <sup>®</sup> Single Dose Vial	1	Wholesaler, Distributor Only	04/2025	3Q 2025	100%
00009-0005-01	Solu-Cortef <sup>®</sup> (hydrocortisone sodium succinate for injection, USP) 1,000 mg/8 mL (125 mg/mL) ACT-O-VIAL <sup>®</sup> Single Dose Vial	1	Wholesaler, Distributor Only	04/2025	3Q 2025	100%

Please note that product status and next delivery estimates may change. We encourage you to check our Pfizer Hospital [Availability Report](#), updated frequently and accessible on the [PfizerHospitalUS.com](https://PfizerHospitalUS.com) homepage, for the latest information.

Thank you for your patience as we work to improve this supply situation. During this interim period, for additional product availability questions, please reach out to your Pfizer Hospital sales representative or account executive. Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 5 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

**Jacqueline Barr**

Portfolio Director, ADD-Vantage, Atgam, and Solu-Cortef

